Development of second primary small-cell lung cancer within the irradiated field after chemoradiotherapy: a report of two cases

Yuki Seike1, Yukio Kawagishi1, Akihito Bando1, Ko Kimoto1, Masato Hongo1 & Shinichi Takeda2

1Department of Respiratory Medicine, Kurobe City Hospital, Kurobe, Japan.
2Department of Internal Medicine, Kurobe City Hospital, Kurobe, Japan.

Keywords
Chemotherapy, lung cancer, oesophageal cancer, radiation-induced tumour, small-cell lung carcinoma.

Abstract
Two male smokers developed small-cell lung cancer (SCLC) as the second primary malignancy (SPM) in the irradiated field after concurrent chemoradiotherapy for locally advanced cancer, which could also be considered as a radiation-induced tumour. A 70-year-old man received cisplatin and S-1 and irradiation at 60 Gy for lung adenocarcinoma eight years previously and an 81-year-old man cisplatin and 5-fluorouracil and at irradiation 60 Gy for oesophageal cancer five years previously. They sequentially received chemotherapy for SCLC, the effects of which were limited, and a refractory course was noted. Chemoradiotherapy is an effective treatment strategy for locally advanced cancer but may be relevant to the onset of SCLC as SPM.

Introduction
Advances in cancer treatment have increased overall survival and improved the cure rates. However, the number of cancer survivors who develop secondary primary malignancy (SPM) is also increasing [1]. Radiation therapy has been one of the mainstays of treatment for a variety of tumours, but it carries a risk of secondary carcinogenesis. Hallmarks of radiation-induced tumours include a long latency period and a tendency to arise within or at the edges of prior treatment fields [1]. Advances in radiation methods and concurrent strategies in combination with chemotherapy result in improved outcomes and may increase the risk of developing radiation-induced tumours. We present two cases of small-cell lung cancer (SCLC) developed within the irradiated field relatively early after chemoradiotherapy.

Case Report
Case 1
A 70-year-old male ex-smoker (60 pack-years) was referred to our hospital complaining of haemoptysis. At the age of 62 years, he had received concurrent chemoradiotherapy (cisplatin and S-1, and thoracic irradiation at 60 Gy) for locally advanced lung adenocarcinoma in the left upper lobe of the lung (cT1bN3M0, stage IIIB) (Fig. 1A, B). He showed complete response with no sign of recurrence after the therapy. Eight years later, chest computed tomography (CT) revealed a tumour in the left upper lobe of the lung and lymph node swelling of the hilum and mediastinum (Fig. 1C, D). Recurrence of adenocarcinoma was suspected initially; however, pathological examination revealed small-cell carcinoma, which was confirmed histologically and immunohistochemically (synaptophysin+, CD56+). The tumour had developed in the previous irradiated field and was therefore considered a radiation-induced tumour. Pro-gastrin-releasing peptide was remarkably higher (2634.9 pg/mL) compared to 27.6 pg/mL when the first primary lung cancer developed eight years ago. He was diagnosed with SCLC (cT1bN3M0, stage IIIA). In spite of limited disease, additional thoracic irradiation was avoided because of overlap with the previous irradiation field. Combination chemotherapy with carboplatin (CBDCA), etoposide (VP-16), and atezolizumab...
was started. Although the tumour shrunk temporarily, progressive disease (PD) was revealed after three courses. Amrubicin (AMR) was started and continued for five courses. Four courses of combination chemotherapy with CBDCA and irinotecan (CPT-11) were followed. Despite a refractory course, he was treated with two additional regimens, but eventually died 13 months after onset.

Case 2

An 81-year-old male smoker (66 pack-years) developed a nodule in the lower lobe of the lung on follow-up CT after the treatment of oesophageal cancer (Fig. 2C). At the age of 77, he underwent current chemoradiotherapy (cisplatin and 5-fluorouracil, and thoracic irradiation at 60 Gy) for locally advanced oesophageal squamous cell carcinoma (cT4aN2M0, stage IVA) (Fig. 2A). He had a complete response, and no recurrence occurred after the therapy. Five years later, a pulmonary nodule developed in the previous irradiated field (Fig. 2B). Echo-guided needle biopsy revealed small-cell carcinoma, which was confirmed histologically and immunohistochemically (synaptophysin+, CD56+). Another small nodule on the left pleura was positive on positron emission tomography, and he was diagnosed with extended disease SCLC with a disseminated pleural lesion (cT1cN0M1a, stage IVA) (Fig. 2D). Combination first-line chemotherapy with CBDCA, VP-16, and atezolizumab was initiated. The therapy yielded a marginal effect, and PD was obvious after three courses. Although AMR was tried as a second-line therapy, no effect was obtained. Combination with CBDCA and CPT-11 was followed yielding no effect. He eventually died six months after the onset of SCLC.

Discussion

The onset of SPM is assumed to be relevant to a variety of factors such as genetics, ageing, smoking, and treatment, including radiotherapy and chemotherapy [1]. Concurrent chemoradiotherapy for locally advanced cancer of the lung and oesophagus has been established as a standard treatment. Platinum-based agents and thoracic radiation are DNA-target therapies that can be expected to have synergistic effects on tumours. The treatment can also derive cancer from DNA damage, which may make it easy for pre-existing aberrant
cells to progress to SPM. The rates of SPM are reportedly 1.8 and 2.9 per 100 patient-years in locally advanced lung cancer treated with concurrent chemoradiotherapy [2]. In locally advanced oesophageal cancer treated with concurrent chemoradiotherapy, the rate is reportedly 19.3% over a five-year cumulative period [3].

We encountered two cases of SCLC with SPM that developed in the irradiated field after chemoradiotherapy. In our review of the literature, there are six patients who developed second primary lung cancer within the irradiated field after chemoradiotherapy; our two cases are addition to these cases (Table 1) [2,4–8]. All patients had a smoking history and received platinum-based chemotherapy. The duration between the onset of first primary cancer and SPM was 1.8–8.7 years, which was shorter than the average onset time of radiation-induced tumours. In six of seven cases, excluding one with SCLC as the first cancer, the histology of the SPM was small-cell carcinoma. This could be a coincidence, and small-cell carcinoma is more likely to be recognized as SPM because non-SCLC was the most common first cancer. However, some cases of SCLC after chemoradiotherapy have been reported to recur within the irradiated field after a long disease-free time of more than a decade [9]. These patients may have developed secondary primary SCLC rather than recurrence. The risk of SCLC onset reportedly increases in patients with Hodgkin’s lymphoma treated with radiotherapy, high-dose atomic bomb survivors, and uranium miners [10].

The major limitation to this report is that the onset in the irradiated field may be accidental. Secondary primary lung cancer may have developed unrelated to radiotherapy because the patients already had sufficient risk factors for lung cancer, and the time to onset may be too short to be considered a radiation-induced tumour.

In conclusion, we report two cases of SCLC that developed in the irradiated field after concurrent chemoradiotherapy for locally advanced cancer of the lung and oesophagus. As the number of long-term survivors increases, a long-term treatment strategy that considers the risk of SPM is likely to be necessary.

**Disclosure Statement**

Appropriate written informed consent was obtained for publication of this case report and accompanying images.
Table 1. Second primary LC within the irradiated field after chemoradiotherapy.

| Author (reference) | Age (years) | Gender | Smoking (pack-year) | First cancer | Chemotherapy | Dose of radiation | Duration (years) | Second cancer | Treatment | Prognosis (months) |
|-------------------|-------------|--------|---------------------|--------------|--------------|-------------------|-----------------|--------------|-----------|-------------------|
| Kawaguchi, 2006 [4] | 66          | M      | +                   | LC (Ad, Sq)  | Platinum doublet | ND                | 7.9             | LC          | (Undiff)  | ND                 |
| Matsui, 2010 [5]  | 77          | F      | 50                  | LC (Sq)      | CBDCA/PTX     | 63.6              | 5               | SCLC        | CBDCA/ CPT-11/ radiation | 9, dead |
| Tanaka, 2015 [6]  | 67          | M      | 120                 | LC (Sq)      | CDDP/MMC/VDS  | 60                | 8               | SCLC        | CDDP/CPT-11 | 12, alive |
| Takano, 2016 [7]  | 81          | M      | 53                  | Mediastinal cancer | CBDCA/PTX | 60 | 3 | SCLC | CBDCA/VP16 | 4, dead |
| Makimoto, 2018 [2] | 68          | M      | +                   | NSCLC        | CDDP/DTX     | 46                | 8.7             | SCLC        | Chemotherapy | 14, dead |
| Inoue, 2019 [8]   | 57          | M      | 37                  | SCLC         | CDDP/VP16    | 36                | 1.8             | LC (Ad)     | Surgery/UFT | ND                 |
| Case 1, 2021      | 70          | M      | 60                  | LC (Ad)      | CDDPS-1      | 60                | 8               | SCLC        | CBDCA/ VP16/Atezo | 13, dead |
| Case 2, 2021      | 81          | M      | 66                  | Oesophageal cancer | CDDP/5-FU | 60 | 5 | SCLC | CBDCA/ VP16/Atezo | 6, dead |

5-FU, 5-fluorouracil; Ad, adenocarcinoma; age at onset of second primary malignancy; Atezo, atezolizumab; CBDCA, carboplatin; CDDP, cisplatin; CPT-11, irinotecan; DTX, docetaxel; LC, lung cancer; MMC, mitomycin C; ND, no data; NSCLC, non-SCLC; PTX, paclitaxel; S1, tegafur/gimeracil/oteracil potassium; SCLC, small-cell lung cancer; Sq, squamous cell carcinoma; UFT, tegafur/uracil; Undiff, undifferentiated; VDS, vindesine; VP16, etoposide.
Author Contribution Statement

Yuki Seike wrote the manuscript. Akihito Bando and Yukio Kawagishi were involved in data interpretation. Ko Kimoto and Masato Hongo were involved in data analysis. Yukio Kawagishi and Shinichi Takeda reviewed and edited the manuscript.

References

1. Wood ME, Vogel V, Ng A, et al. 2012. Second malignant neoplasms: assessment and strategies for risk reduction. J. Clin. Oncol. 30:3734–3745.
2. Makimoto G, Kubo T, Oze I, et al. 2018. Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. Jpn. J. Clin. Oncol. 48:287–290.
3. Yamaguchi T, Kato K, Nagashima K, et al. 2018. Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. Int. J. Clin. Oncol. 23:652–658.
4. Kawaguchi T, Matsumura A, Iuchi K, et al. 2006. Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy. Jpn. J. Clin. Oncol. 36:7–11.
5. Matsui C, Kono T, Terada Y, et al. 2010. A case of small cell lung cancer appeared in field irradiated for previous squamous cell carcinoma of the lung. Jpn. J. Lung Cancer 50:912–915 (In Japanese).
6. Tanaka S, Ueno T, Suehisa H, et al. 2015. A case report of radiation-induced small cell lung cancer in the irradiation field for squamous cell carcinoma of the lung. Jpn. J. Lung Cancer 55:9–13 (In Japanese).
7. Takano S, Majima H, Hara T, et al. 2016. Radiation-induced lung cancer after chemoradiotherapy for mediastinal cancer. J. Jpn. Soc. Respir. Endosc. 38:365–370 (In Japanese).
8. Inoue T, Murakami J, Sano F, et al. 2016. A case of second primary lung cancer developing after chemoradiotherapy for small cell lung cancer. Jpn. J. Chest Surg. 30:584–588 (In Japanese).
9. Asano F, Watanabe K, Shinkai M, et al. 2016. Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period. Chin. J. Cancer 35:63.
10. Travis LB, Gospodarowicz M, Curtis RE, et al. 2002. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J. Natl. Cancer Inst. 94:182–192.